Zobrazeno 1 - 10
of 403
pro vyhledávání: ''
Autor:
Eugene Zhu, Maria R. Baer, Dietger Niederwieser, Olatoyosi Odenike, Souria Dougherty, Laurie Sherman, Libo Sun, John Mascarenhas, Aleksandra Rizo, Fei Huang, Rami S. Komrokji, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Bruno Martino, Francesca Palandri, Ying Wan, Jacqueline Bussolari, Ronald Hoffman, Faye Feller, Andreas Reiter, Esther Rose
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(26)
PURPOSE Patients with myelofibrosis who are relapsed or refractory (R/R) to Janus-associated kinase inhibitors (JAKis) have poor clinical outcomes including dismal overall survival (OS) that ranges between 13 and 16 months. Imetelstat, a telomerase i
Autor:
Jing Wu, Janet E. Cowan, Peter R. Carroll, Markus Graefen, Ming-Hui Chen, Derya Tilki, Dirk Böhmer, Alan W. Partin, Anthony V. D'Amico, Osama Mohamad, F.Y. Feng, Bruce J. Trock, Hartwig Huland, Thomas Wiegel
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(20)
PURPOSE Adjuvant compared with early salvage radiation therapy (sRT) following radical prostatectomy (RP) has not been shown to reduce progression-free survival in randomized controlled trials. However, these trials might have missed a benefit in men
Autor:
Yvonne Suessmuth, Shalini Shenoy, Catherine Bresee, Alison Yu, Amelia Langston, Scott N. Furlan, Andrew C. Harris, Steven E. Bosinger, Muna Qayed, Sungjin Kim, Brandi Bratrude, Maxim Norkin, Audrey G. Tumlin, Jeffrey H. Davis, James Rhodes, John T. Horan, Courtney McCracken, Urvi Kapoor, Alexandria Narayan, Leslie S. Kean, Kayla Betz, Benjamin Watkins, John E. Levine, Bruce R. Blazar, Aleksandra Petrovic, Sung Won Choi, Kayla Cribbin, Michael Grimley, James L.M. Ferrara, Scott Gillespie, Kyle Hebert, Ted Gooley, Marcelo C. Pasquini, Shauna Sinclair, Michael A. Pulsipher, Mourad Tighiouart, Roger Giller, David A. Jacobsohn, Nahal R. Lalefar, Kirk R. Schultz, Christine Duncan, Edmund K. Waller, Gregory A. Yanik, Victor Tkachev, Andre Rogatko, Nosha Farhadfar
Publikováno v:
J Clin Oncol
PURPOSE Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no
Autor:
Martin R. Weiser, Ajaratu Keshinro, Zsofia K. Stadler, William C. Chapman, J. Joshua Smith, Emmanouil P. Pappou, Efsevia Vakiani, Iris H Wei, Tsuyoshi Konishi, Garrett M. Nash, Andrea Cercek, Maria Widmar, Philip B. Paty, Julio Garcia-Aguilar, Yoshifumi Shimada, Meier Hsu, Mithat Gonen, Iván González, Philip S. Bauer, Jinru Shia, Leonard B. Saltz, Neil H. Segal, Deepak Lingam, Rona Yaeger, Matthew G. Mutch, Deyali Chatterjee, Anna M. Varghese
Publikováno v:
J Clin Oncol
PURPOSE Clinical calculators and nomograms have been endorsed by the American Joint Committee on Cancer (AJCC), as they provide the most individualized and accurate estimate of patient outcome. Using molecular and clinicopathologic variables, a third
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(36)
Autor:
Hélène Senellart, Sung Bae Kim, Takashi Kojima, Antoine Adenis, Shukui Qin, Peter C. Enzinger, Jaafar Bennouna, Jia Chen, Toshihiko Doi, Jean-Philippe Metges, Ken Kato, Lin Shen, Christelle De La Fouchardiere, Kei Muro, Eric Francois, Toshikazu Moriwaki, Keynote Investigators, S. Peter Kang, Shailaja Suryawanshi, Se-Hoon Lee, Ruixue Wang, Raed Al-Rajabi, Florian Lordick, Paula Ferreira, Gustavo Girotto, Chih-Hung Hsu, Manish A. Shah, Pooja Bhagia
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(35)
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metast
Autor:
Masakazu Toi, Joyce O'Shaughnessy, Investigators, Valentina Guarneri, Ran Wei, Maarten Hulstijn, Irfan Cicin, Mario Campone, Frances M. Boyle, Jens Huober, Patrick Neven, Erika Hamilton, Belen San Antonio, Morihito Okada, Sara M. Tolaney, Andrew M Wardley, Roberto Hegg, Desiree Headley, Stephen R. D. Johnston, Martin Frenzel, Q. Zhang, Priya Rastogi, Zhi Min Shao, Jorge Luis Martinez Rodriguez, Miguel Martín, Javier Cortes, Ian C. Smith, Nadia Harbeck, Joohyuk Sohn, Joanne Cox
Publikováno v:
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology
Càncer de mama precoç; Teràpia endocrina; Abemaciclib Cáncer de mama precoz; Terapia endocrina; Abemaciclib Early Breast Cancer; Endocrine Therapy; Abemaciclib PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
Autor:
Masahiro Kashiwaba, Tsuyoshi Saito, Michiko Tsuneizumi, Hiroji Iwata, Noriko Sagawa, Hiroaki Kawashima, Takuya Kawahara, Miki Yamaguchi, Yasuo Ohashi, Tsutomu Takashima, Masataka Sawaki, Toshiro Mizuno, Naruto Taira, Shinichi Baba, Yutaka Yamamoto, Hirofumi Mukai, Yukari Uemura, Takahiro Nakayama, Hiroko Bando, Masato Takahashi, Kokoro Kobayashi
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(32)
PURPOSE Adjuvant trastuzumab monotherapy has not been compared with trastuzumab + chemotherapy. We investigated the relative value of trastuzumab monotherapy for older patients with breast cancer. METHODS This study was an open-label, randomized cont
Autor:
Ang Li, Jason C. Chandler, Davey B. Daniel, Félix Couture, Sunil Babu, Vijay Gunuganti, Maen A. Hussein, Robert M. Jotte, Samer Kasbari, Michael McCleod, Edward B. Garon, Justin N. Baker, Nivedita Aanur, Lawrence H. Einhorn, Leora Horn, Ben C. Creelan, Petros Nikolinakos, George P. Keogh, David R. Spigel, Craig Reynolds, Natasha B. Leighl, David M. Waterhouse, George R. Blumenschein
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(33)
PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-y
Autor:
Eric J. Small, Martin E. Gleave, Mary-Ellen Taplin, Saby George, Susan Halabi, Christopher P. Evans, David W. Hillman, Himisha Beltran, J. Kellogg Parsons, Olwen Hahn, James L. Mohler, Russell Z. Szmulewitz, Glenn Heller, Michael J. Morris, James A. Eastham, Martin G. Sanda, Jonathan A. Coleman, J. Paul Monk, Colleen Watt, Steven K. Clinton
Publikováno v:
J Clin Oncol
PURPOSERadical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would imp